1 / 3

Boceprevir e Telaprevir: l ’ inizio di una nuova era nel genotipo 1

Boceprevir e Telaprevir: l ’ inizio di una nuova era nel genotipo 1. Il futuro ?. 100 80 60 40 20 0. Futuro ?. 63–79%. DAA + Peg-IFN + RBV 5,6. 42–54%. SVR (%). Peg-IFN + RBV 2–4. 16–28%. IFN + RBV 1. 2–7%. IFN 1. 1990 2000 2011 2020.

tokala
Download Presentation

Boceprevir e Telaprevir: l ’ inizio di una nuova era nel genotipo 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Boceprevir e Telaprevir:l’inizio di una nuova era nel genotipo 1

  2. Il futuro ? 100 80 60 40 20 0 Futuro? • 63–79% DAA+Peg-IFN + RBV5,6 • 42–54% SVR (%) Peg-IFN + RBV2–4 • 16–28% IFN+ RBV1 • 2–7% IFN1 1990 2000 2011 2020 1. McHutchison JG, et al. N Engl J Med 1998;339:1485–92; 2. Fried M, et al. N Engl J Med 2002;347:975–823. Manns MP, et al. Lancet 2001;358:958–65; 4. Hadziyannis SJ, et al. Ann Intern Med 2004;140:346–555. Telaprevir EU SmPC; 6. Boceprevir EU SmPC

  3. Terapia dell’epatite C: adesso e in futuro orale orale IFN IFN orale orale [ ] Ribavirina Ribavirina Prima generazione degli inibitori delle proteasi

More Related